Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nathan Clements

Interventional Pain Medicine Saint George, UT Medical Doctor

NPI 1740716232 CMS profile 11303669

617 E Riverside Dr Ste 301, Saint George, UT 84790

Open in the dashboard

General payments

$29,437

305 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Clements of Saint George, UT is reported in the CMS Open Payments database as having received $29,437 across 305 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,172 68
2024 General $1,615 69
2023 General $2,486 75
2022 General $5,499 82
2021 General $16,665 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Clements
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Nathan Clements were reported at $3,172. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Nathan Clements Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $16,665 $552 $167–$1,554 $132
2022 $5,499 $605 $187–$1,924 $149
2023 $2,486 $671 $195–$1,915 $160
2024 $1,615 $684 $206–$1,837 $164
2025 $3,172 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $19,541 102 payments
  2. Abbott Laboratories $2,681 24 payments
  3. Medtronic, Inc. $2,331 50 payments
  4. SPR Therapeutics, Inc $1,292 17 payments
  5. Relievant Medsystems, Inc. $1,136 13 payments
  6. Nevro Corp. $970 35 payments
  7. AbbVie, Inc. $421 21 payments
  8. MML US, Inc. $176 2 payments
  9. SI-BONE, Inc. $120 1 payment
  10. Nalu Medical, Inc. $114 6 payments
  11. Other $657 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $15,000 1 payment
  2. Food and Beverage $9,875 281 payments
  3. Travel and Lodging $4,562 23 payments
Products named General payments · program years 2021–2025
  1. WAVEWRITER ALPHA $15,533 3 payments
  2. SYNCHROMEDII $1,512 15 payments
  3. SPRINT PNS System $1,259 16 payments
  4. PRODIGY $1,231 4 payments
  5. Intracept Pain $1,136 13 payments
  6. Intracept Pain $986 11 payments
  7. Intracept Pain $986 11 payments
  8. Intracept Pain $986 11 payments
  9. PROCLAIM $899 8 payments
  10. Artisan $807 21 payments
  11. Other $6,321 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

825

Median for Pain Management: 951

Drug cost

$11,834

Median for Pain Management: $26,034

Branded share of claims

29.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 183 $2,947
Pregabalin Generic 80 $1,699
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 64 $1,279
Celecoxib Generic 50 $1,149
Duloxetine Hcl Generic 62 $1,147
Gabapentin Generic 92 $1,094
Cephalexin Generic 53 $419
Oxycodone Hcl Generic 27 $409
Tramadol Hcl Generic 60 $384
Tizanidine Hcl Generic 38 $311

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$571,155

Of which drugs: $11,691

Medicare patients

848

Average age 75

Services billed

11,263

457 women, 391 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 24%
Ischemic heart disease 23%
Chronic kidney disease 23%
Diabetes 22%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 15 992 $6,993
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 637 5,841 $4,472
Injection, fentanyl citrate, 0.1 mg J3010 Office 103 138 $99
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 46 441 $39
Injection, midazolam hydrochloride, per 1 mg J2250 Office 107 360 $38
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 21 $11
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 19 99 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $120
$120 — —
QULIPTA
  • AbbVie, Inc. $80
$80 — —
UBRELVY
  • AbbVie, Inc. $62
$62 — —
NURTEC ODT
  • PFIZER INC. $58
$58 — —
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

305 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record